• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Modelling downstream effects in the presence of technological change.

作者信息

Mortimer Duncan

机构信息

Centre for Health Economics, Faculty of Business & Economics, Monash University, Melbourne, Victoria, Australia.

出版信息

Pharmacoeconomics. 2008;26(12):991-1003. doi: 10.2165/0019053-200826120-00003.

DOI:10.2165/0019053-200826120-00003
PMID:19014201
Abstract

Downstream effects are typically evaluated given current technology and current practice patterns rather than for technology and practice patterns that will be available at the time when downstream effects accrue. Where a relatively short time horizon can be expected to capture all relevant costs and effects, the current approach is unlikely to introduce substantial error into estimates of the costs and benefits attributed to an intervention; the estimates will remain valid so long as the context to which estimates relate remains unchanged. However, for longer time horizons, the magnitude of error associated with the current approach might be substantial. This paper describes three strategies for incorporating uncertainty associated with technological change into modeled economic evaluations: (i) discounting; (ii) within-trial analysis; and (iii) threshold/sensitivity analysis with horizon scanning. The appropriateness of each strategy for handling uncertainty associated with technological change is then considered under various possible situations defined over the characteristics of technological change (pace and whether technological change produces interventions that are dominant, cost increasing or cost saving) and the characteristics of downstream effects (proximity and the sensitivity of policy recommendations to their inclusion/exclusion). Selecting the appropriate strategy (or strategies) for the situation should permit estimation of more realistic upper and lower bounds around base-case estimates.

摘要

相似文献

1
Modelling downstream effects in the presence of technological change.
Pharmacoeconomics. 2008;26(12):991-1003. doi: 10.2165/0019053-200826120-00003.
2
3
4
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.巴雷特食管的监测:通过系统评价、专家研讨会和经济模型探索不确定性
Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080.
5
The economic valuation of improved process plant decision support technology.
ISA Trans. 2007 Jun;46(3):437-42. doi: 10.1016/j.isatra.2007.01.003. Epub 2007 Apr 16.
6
Discounting in health care decision-making: time for a change?医疗保健决策中的贴现:是时候做出改变了吗?
J Public Health Med. 1992 Sep;14(3):250-6.
7
Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.预算影响分析——良好实践原则:ISPOR 2012 预算影响分析良好实践 II 工作组报告。
Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].[精神分裂症患者护理环境的成本效益分析:长效注射制剂下非典型抗精神病药物的影响]
Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5.
10
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.疾病修正治疗缓解复发型多发性硬化症的成本效益分析中的建模方法:更新的系统评价和对未来经济评估的建议。
Pharmacoeconomics. 2018 Oct;36(10):1223-1252. doi: 10.1007/s40273-018-0683-9.

本文引用的文献

1
The value of medical spending in the United States, 1960-2000.1960年至2000年美国医疗支出的价值。
N Engl J Med. 2006 Aug 31;355(9):920-7. doi: 10.1056/NEJMsa054744.
2
Whither trial-based economic evaluation for health care decision making?基于试验的卫生保健决策经济评估何去何从?
Health Econ. 2006 Jul;15(7):677-87. doi: 10.1002/hec.1093.
3
Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.心脏再同步治疗的成本效益:来自CARE-HF试验的结果。
Eur Heart J. 2005 Dec;26(24):2681-8. doi: 10.1093/eurheartj/ehi662. Epub 2005 Nov 11.
4
Taking account of future technology in cost effectiveness analysis.在成本效益分析中考虑未来技术。
BMJ. 2004 Sep 25;329(7468):733-6. doi: 10.1136/bmj.329.7468.733.
5
Generalized cost-effectiveness analysis for national-level priority-setting in the health sector.卫生部门国家级优先事项设定的广义成本效益分析。
Cost Eff Resour Alloc. 2003 Dec 19;1(1):8. doi: 10.1186/1478-7547-1-8.
6
Is technological change in medicine worth it?医学领域的技术变革值得吗?
Health Aff (Millwood). 2001 Sep-Oct;20(5):11-29. doi: 10.1377/hlthaff.20.5.11.
7
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.低剂量与高剂量血管紧张素转换酶抑制剂赖诺普利治疗慢性心力衰竭的成本效益分析:基于赖诺普利治疗与生存评估(ATLAS)研究。ATLAS研究小组
Eur J Heart Fail. 2000 Dec;2(4):447-54. doi: 10.1016/s1388-9842(00)00122-7.
8
On what basis should health be discounted?
J Health Econ. 1993 Apr;12(1):39-53. doi: 10.1016/0167-6296(93)90039-h.
9
Discounting costs and effects: a reconsideration.成本与效果的贴现:重新审视
Health Econ. 1998 Nov;7(7):581-94. doi: 10.1002/(sici)1099-1050(1998110)7:7<581::aid-hec380>3.0.co;2-u.
10
Modelling in economic evaluation: an unavoidable fact of life.经济评估中的建模:生活中不可避免的事实。
Health Econ. 1997 May-Jun;6(3):217-27. doi: 10.1002/(sici)1099-1050(199705)6:3<217::aid-hec267>3.0.co;2-w.